Table 2.

Antibiotic nonsusceptibility rates of pneumococcal isolates collected from IPD, non-BPP, and AE-COPD in the period of 2013–2016

Antibiotics	IPD		non-BPPa		AE-COPD		Total
	n=57	%R	n=78	%R	n=210	%R	n=345	%R
Penicillinb	15	26.32	15	19.23	96	45.71c	126	36.52
0.12–1 mg/L	10	17.54	8	10.26	60	28.57	78	22.61
2 mg/L	3	5.26	3	3.85	26	12.38	32	9.28
≥4 mg/Ld	2	3.51	4	5.13	10	4.76	16	4.64
Cefotaximeb	6	10.53	8	10.26	25	11.90	39	11.30
1 mg/L	5	8.77	5	6.41	20	9.52	30	8.70
≥2 mg/Ld	1	1.75	3	3.85	5	2.38	9	2.61
Amoxicillind	2	3.51	5	6.41	25	11.90c	32	9.28
4 mg/Ld	1	1.75	5	6.41	21	10.00	27	7.83
≥8 mg/Ld	1	1.75	0	0.00	4	1.90	5	1.45
Erythromycin	9	15.79	11	14.10	80	38.10c	100	28.99
Clindamycin	8	14.04	9	11.54	72	34.29c	89	25.80
Tetracycline	18	31.58	16	20.51	87	41.43c	121	35.07
Chloramphenicol	6	10.53	5	6.41	9	4.29	20	5.80
Cotrimoxazole	12	21.05	16	20.51	69	32.86	97	28.12
Levofloxacin	1	1.75	1	1.28	20	9.52	22	6.38
Multiresistance	12	21.05	10	12.82	77	36.67c	99	28.70

Notes:

^aThere were no statistically significant differences among resistance rates of IPD and non-BPP;

^boverall nonsusceptible following meningeal criteria;

^cresistance rates of AE-COPD pneumococci significantly higher (p<0.05) than among IPD or non-BPP isolates;

^dnonsusceptible for nonmeningeal infections. %R indicates the percentage of resistance to each antibiotic among the number that is given on each group (IPD, non-BPP, AECOPD and Total).

Abbreviations: AE-COPD, acute exacerbation of chronic obstructive pulmonary disease; IPD, invasive pneumococcal disease; non-BPP, non-bacteremic pneumococcal pneumonia.